10.22.21
Johnson & Johnson’s Q3 sales grew 10.7% to $23.3 billion. Earnings per share of $1.37 increased to 3.0%, and adjusted earnings per share of $2.60 increased to 18.2%.
"Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in pharmaceuticals, ongoing recovery in medical devices, and strong growth in consumer health," said Alex Gorsky, chairman and chief executive officer. "In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth.”
Consumer health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 5.7% primarily driven by OTC products. Major contributors to growth included Aveeno in skin health/beauty.